Loading the company…
Loading the company…
In 2025, Instylla reported engagement with 28 surgeons and other clinicians in the states MedaRep covers, worth $99K in consulting, speaking, meals and travel for its device products, the most in California ($64K to 5). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($64K, 5 engaged), Massachusetts ($14K, 5 engaged), New York ($11K, 4 engaged), Pennsylvania ($6,073, 3 engaged), Georgia ($2,250, 1 engaged).
In the last ten years FDA made 10 decisions for Instylla (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (5). The latest was on 2026-09-03.
| Family | Decisions on record |
|---|---|
| Tumor & fibroid embolization | 10 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-09-03 | PMA | P250003-S009 | Embrace Hydrogel Embolic System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-04-02 | PMA | P250003-S005 | Embrace Hydrogel Embolic System (HES) · Change Design/Components/Specifications/Material |
| 2026-04-01 | PMA | P250003-S006 | Embrace Hydrogel Embolic System (HES) · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-02-12 | PMA | P250003-S004 | Embrace Hydrogel Embolic System (HES) · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-02-04 | PMA | P250003-S003 | Embrace Hydrogel Embolic System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Instylla.